{"id":"NCT02604433","sponsor":"Celgene","briefTitle":"An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Adults Who Require Regular Red Blood Cell Transfusions Due to Beta (β) Thalassemia","officialTitle":"A Phase 3, Double-Blind, Placebo Controlled Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) in Adults With Transfusion Dependent Beta (B)-Thalassemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-02","primaryCompletion":"2021-01-05","completion":"2021-01-05","firstPosted":"2015-11-13","resultsPosted":"2020-01-27","lastUpdate":"2023-04-18"},"enrollment":336,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Erythrocyte Transfusion","Beta-Thalassemia"],"interventions":[{"type":"DRUG","name":"Luspatercept","otherNames":["ACE-536"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Luspatercept (ACE-536) plus Best Supportive Care (BSC)","type":"EXPERIMENTAL"},{"label":"Placebo plus Best Supportive Care (BSC)","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3, double-blind, randomized, placebo-controlled, multicenter study to determine the efficacy and safety of luspatercept (ACE-536) plus Best supportive care (BSC) versus placebo plus BSC in adults who require regular red blood cell transfusion due to (β)-thalassemia.\n\nThe study is divided into the following periods:\n\n* Historical Period,\n* Screening/Run-in Period,\n* Double-blind Treatment Period (48 weeks),\n* Double-blind Long-term Treatment Period, (at the investigator's discretion an additional 48 weeks),\n* Open-Label Phase post unblinding and upon Data Monitoring Committee positive recommendation\n* Post-treatment Follow-up Period","primaryOutcome":{"measure":"Percentage of Participants Who Achieved Erythroid Response - Week 13 to Week 24","timeFrame":"Baseline: Day -83 to Day 1; Treatment: Weeks 13 to Week 24","effectByArm":[{"arm":"Luspatercept + BSC","deltaMin":21,"sd":null},{"arm":"Placebo + BSC","deltaMin":4.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":76,"countries":["United States","Australia","Bulgaria","Canada","France","Greece","Israel","Italy","Lebanon","Malaysia","Taiwan","Thailand","Tunisia","Turkey (Türkiye)","United Kingdom"]},"refs":{"pmids":["30504333","30617198","39947215","37782758","37704579","33570654","32212518"],"seeAlso":["https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html","https://www.bmsstudyconnect.com/s/US/English/USenHome","https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":53,"n":223},"commonTop":["Upper respiratory tract infection","Back pain","Headache","Pyrexia","Arthralgia"]}}